The Anti-tumor Activity of Vitamin C via the Increase of Fas (CD95) and MHC I expression on Human Stomach Cancer Cell Line, SNU1
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
It is already known that high concentration of vitamin C induces apoptosis on tumor cells. However, there is no report regarding the function of vitamin C on the modulation of immune susceptibility of cancer. Therefore, we investigated whether vitamin C can modulate immune susceptibility of tumor cells, especially on the induction of Fas-mediated apoptosis. First, the optimal concentration of vitamin C, which cannot induce damages on tumor cells for 36 hrs. We found that 2 mM of vitamin C did not show harmful effect. In addition, the optimal concentration of agonistic anti-Fas Abs for 18 hrs was examined. As a result, 400 ng/ml of agonistic anti-Fas Abs did not induce apoptosis on tumor cells. Next, we tried to find the effect of 2 mM of vitamin C on the modulation of the susceptibility to agonistic anti-Fas Abs. When tumor cells were cultured with 400 ng/ml of agonistic anti-Fas Abs for 18 hrs, after pre-treatment with 2 mM of vitamin C for 24 hrs, viability of cells was decreased. Interestingly, we found that the expression of Fas (CD95) and MHC class I was increased by the treatment of vitamin C. Taken together, vitamin C increases the susceptibility of tumor cells to anti-Fas Abs and the expression of Fas (CD95) and MHC class I on tumor cells.
Abstract
It is already known that high concentration of vitamin C induces apoptosis on tumor cells. However, there is no report regarding the function of vitamin C on the modulation of immune susceptibility of cancer. Therefore, we investigated whether vitamin C can modulate immune susceptibility of tumor cells, especially on the induction of Fas-mediated apoptosis. First, the optimal concentration of vitamin C, which cannot induce damages on tumor cells for 36 hrs. We found that 2 mM of vitamin C did not show harmful effect. In addition, the optimal concentration of agonistic anti-Fas Abs for 18 hrs was examined. As a result, 400 ng/ml of agonistic anti-Fas Abs did not induce apoptosis on tumor cells. Next, we tried to find the effect of 2 mM of vitamin C on the modulation of the susceptibility to agonistic anti-Fas Abs. When tumor cells were cultured with 400 ng/ml of agonistic anti-Fas Abs for 18 hrs, after pre-treatment with 2 mM of vitamin C for 24 hrs, viability of cells was decreased. Interestingly, we found that the expression of Fas (CD95) and MHC class I was increased by the treatment of vitamin C. Taken together, vitamin C increases the susceptibility of tumor cells to anti-Fas Abs and the expression of Fas (CD95) and MHC class I on tumor cells.
참고문헌 (21)
- Kang JS, "L-ascorbic acid (vitamin C) induces the apoptosis of B16 murine melanoma cells via a caspase-8-independent pathway", Cancer Immunol Immunother, 52, pp.693~698 (2003)
- Kang JS, "Sodium ascorbate (vitamin C) induces apoptosis in melanoma cells via the down-regulation of transferrin receptor dependent iron uptake", Journal of Cellular Physiology, 204(1), pp.192~197 (2005), John Wiley & Sons Inc.
- Kim JE, "Vitamin C inhibits p53-induced replicative senescence through suppression of ROS production and p38 MAPK activity", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 22, pp.651~655 (2008), PROFESSOR D A SPANDIDOS
- Hahm E, "The molecular mechanisms of vitamin C on cell cycle regulation in B16F10 murine melanoma", JOURNAL OF CELLULAR BIOCHEMISTRY, 102, pp.1002~1010 (2007), WILEY-LISS
- Lee SK, "Vitamin C suppresses proliferation of the human melanoma cell SK-MEL-2 through the inhibition of cyclooxygenase-2 (COX-2) expression and the modulation of insulin-like growth factor IIIGF-II production", JOURNAL OF CELLULAR PHYSIOLOGY, 216, pp.180~188 (2008), WILEY-LISS
- Kim HN, "Vitamin C down-regulates VEGF production in B16F10 murine melanoma cells via the suppression of p42", 44 MAPK activation, 201103, pp.112(3), 894~901[DOI]
- Cho D, "Vitamin C downregulates interleukin-18 production by increasing reactive oxygen intermediate and mitogen-activated protein kinase signalling in B16F10 murine melanoma cells", MELANOMA RESEARCH, 13, pp.549~554, LIPPINCOTT WILLIAMS & WILKINS
- Hong SW, "Ascorbate (vitamin C) induces cell death through the apoptosis-inducing factor in human breast cancer cells", Oncol Rep, 18, pp.811~815 (2007)
- Ferrone S, "Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance", Immunol Today, 16, pp.487~494 (1995)
- Hahne M, "Melanoma cell expression of Fas (Apo-1", CD95) ligand: implications for tumor immune escape, 1996, pp.274, 1363~1366
- Krammer PH, "CD95’s deadly mission in the immune system", Nature, 407, pp.789~795 (2000)
- Kroemer G, "Mitochondrial control of apoptosis", Immunol Today, 18, pp.44~51 (1997)
- Rosenberg SA, "Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer", N Engl J Med, 313, pp.1485~1492 (1985)
- West WH, "Constant-infusion recombinant interleukin- 2 in adoptive immunotherapy of advanced cancer", N Engl J Med, 316, pp.898~905 (1987)
- Thurner B, "Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma", J Exp Med, 190, pp.1669~1678 (1999)
- Nestle FO, "Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells", Nat Med, 4, pp.328~332 (1998)
- Siegel BV, "Vitamin C and immunity: natural killer (NK) cell factor", Int J Vitam Nutr Res, 53, pp.179~183 (1983)
- 진동훈, "Vitamin C-treated murine bone marrow-derived dendritic cells preferentially drive naïve T cells into Th1 cells by increased IL-12 secretions", Cellular Immunology, 266(2), pp.192~199 (2011), Academic Press
- Levine M, "Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance", Proc Natl Acad Sci U S A, 93, pp.3704~3709 (1996)
- Levine M, "A new recommended dietary allowance of vitamin C for healthy young women", Proc Natl Acad Sci U S A, 98, pp.9842~9846 (2001)
- Padayatty SJ, "Vitamin C pharmacokinetics: implications for oral and intravenous use", Ann Intern Med, 140, pp.533~537 (2004)